tetano
Editor, Senior Moderator
PLoS One. 2014 Jul 30;9(7):e103550. doi: 10.1371/journal.pone.0103550. eCollection 2014.
Transient Humoral Protection against H5N1 Challenge after Seasonal Influenza Vaccination of Humans.
Roozendaal R1, Tolboom J1, Roos A1, Riahi S1, Theeuwsen J1, Bujny MV1, Klaren V1, Korse HJ1, Dekking L1, Grootenhuis A2, Weverling GJ1, Koudstaal W1, Goudsmit J1, Rado?ević K1.
Author information
Abstract
Current influenza vaccines are believed to confer protection against a narrow range of virus strains. The identification of broadly influenza neutralizing antibodies (bnAbs) has triggered efforts to develop vaccines providing 'universal' protection against influenza. Several bnAbs were isolated from humans recently vaccinated with conventional influenza vaccines, suggesting that such vaccines could, in principle, be broadly protective. Assessing the breadth-of-protection conferred to humans by influenza vaccines is hampered by the lack of in vitro correlates for broad protection. We designed and employed a novel human-to-mouse serum transfer and challenge model to analyze protective responses in serum samples from clinical trial subjects. One dose of seasonal vaccine induces humoral protection not only against vaccine-homologous H1N1 challenge, but also against H5N1 challenge. This heterosubtypic protection is neither detected, nor accurately predicted by in vitro immunogenicity assays. Moreover, heterosubtypic protection is transient and not boosted by repeated inoculations. Strategies to increase the breadth and duration of the protective response against influenza are required to obtain 'universal' protection against influenza by vaccination. In the absence of known correlates of protection for broadly protective vaccines, the human-to-mouse serum transfer and challenge model described here may aid the development of such vaccines.
PMID:
25075622
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/25075622
Transient Humoral Protection against H5N1 Challenge after Seasonal Influenza Vaccination of Humans.
Roozendaal R1, Tolboom J1, Roos A1, Riahi S1, Theeuwsen J1, Bujny MV1, Klaren V1, Korse HJ1, Dekking L1, Grootenhuis A2, Weverling GJ1, Koudstaal W1, Goudsmit J1, Rado?ević K1.
Author information
Abstract
Current influenza vaccines are believed to confer protection against a narrow range of virus strains. The identification of broadly influenza neutralizing antibodies (bnAbs) has triggered efforts to develop vaccines providing 'universal' protection against influenza. Several bnAbs were isolated from humans recently vaccinated with conventional influenza vaccines, suggesting that such vaccines could, in principle, be broadly protective. Assessing the breadth-of-protection conferred to humans by influenza vaccines is hampered by the lack of in vitro correlates for broad protection. We designed and employed a novel human-to-mouse serum transfer and challenge model to analyze protective responses in serum samples from clinical trial subjects. One dose of seasonal vaccine induces humoral protection not only against vaccine-homologous H1N1 challenge, but also against H5N1 challenge. This heterosubtypic protection is neither detected, nor accurately predicted by in vitro immunogenicity assays. Moreover, heterosubtypic protection is transient and not boosted by repeated inoculations. Strategies to increase the breadth and duration of the protective response against influenza are required to obtain 'universal' protection against influenza by vaccination. In the absence of known correlates of protection for broadly protective vaccines, the human-to-mouse serum transfer and challenge model described here may aid the development of such vaccines.
PMID:
25075622
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/25075622